Table 2.
Distribution of patients with FGF/FGFR alterations across different tumor types.
| FGFR Amplification | FGFR SNV | FGFR Fusion | FGF Amplification | FGF SNV | FGF Fusion | |
|---|---|---|---|---|---|---|
| Total | 2.9% | 5.1% | 0.9% | 5.1% | 3.9% | 0.1% |
| Esophagus cancer | 8.2% | 6.3% | 0.0% | 38.4% | 8.8% | 0.0% |
| Urinary Tract cancer | 5.1% | 19.6% | 5.8% | 16.7% | 5.5% | 0.0% |
| Head and Neck cancer | 2.3% | 3.5% | 1.9% | 21.0% | 3.5% | 0.0% |
| Breast cancer | 8.4% | 4.3% | 0.5% | 8.9% | 3.0% | 0.3% |
| Endometrium cancer | 1.5% | 15.4% | 0.0% | 1.5% | 5.9% | 0.0% |
| Gastric cancer | 5.3% | 6.2% | 1.8% | 4.5% | 5.7% | 0.1% |
| Colorectal cancer | 2.6% | 7.2% | 0.4% | 3.9% | 5.1% | 0.0% |
| Liver cancer | 1.2% | 4.8% | 1.0% | 7.7% | 3.2% | 0.2% |
| Lung cancer | 3.1% | 5.3% | 0.4% | 4.0% | 5.1% | 0.0% |
| Intestine cancer | 0.8% | 4.8% | 0.8% | 6.5% | 4.0% | 0.0% |
| Melanoma | 5.0% | 3.8% | 0.6% | 3.8% | 3.1% | 0.0% |
| Other | 2.8% | 2.4% | 0.9% | 4.8% | 3.3% | 0.2% |
| Ovarian cancer | 4.1% | 4.8% | 0.3% | 2.4% | 2.0% | 0.0% |
| Cervical cancer | 1.0% | 7.7% | 1.0% | 0.0% | 3.6% | 0.0% |
| Biliary Tract cancer | 2.0% | 4.1% | 2.4% | 2.8% | 1.6% | 0.0% |
| Neuroendocrine cancer | 4.5% | 1.1% | 1.1% | 2.2% | 0.0% | 0.0% |
| Sarcoma | 2.7% | 1.9% | 0.0% | 3.0% | 1.4% | 0.0% |
| Thyroid cancer | 2.6% | 5.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| GIST | 3.0% | 1.5% | 1.5% | 1.5% | 0.0% | 0.0% |
| Prostate cancer | 3.2% | 2.1% | 2.1% | 0.0% | 0.0% | 0.0% |
| Pancreatic cancer | 2.0% | 1.3% | 0.2% | 1.1% | 2.5% | 0.0% |
| Kidney cancer | 0.2% | 2.2% | 0.4% | 0.0% | 1.6% | 0.0% |